BILL ANALYSIS

HR7118

BULLISH

Genomic Answers for Children’s Health Act of 2026

HR7118 (Genomic Answers for Children’s Health Act of 2026) carries an AI-assessed market impact score of 4/10 with a bullish outlook for investors. This legislation directly affects $ILMN, Thermo Fisher Scientific ($TMO), $PACB and $BNGO and 1 other ticker. The primary sectors impacted are Healthcare and Technology. View the full bill text on Congress.gov.

4/10

Impact Score

bullish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR7118 mandates Medicaid coverage for whole genome and whole exome sequencing for children with specific medical needs, creating a new revenue stream for genomic companies.

The bill is currently in the early stages, having been introduced and referred to the House Committee on Energy and Commerce.

Companies like Illumina, Thermo Fisher Scientific, Pacific Biosciences, Bionano Genomics, and Fulgent Genetics are direct beneficiaries of this expanded coverage.

How HR7118 Affects the Market

The Genomic Answers for Children’s Health Act of 2026, if enacted, would structurally increase the addressable market for genomic sequencing services within the Medicaid program. This would directly benefit companies providing these technologies and services. While the bill does not appropriate new funds, it mandates coverage, ensuring payment for these services through the existing Medicaid framework. This represents a long-term positive catalyst for the genomic sequencing sector. Recent market performance for key players shows mixed 30-day trends but generally positive 7-day movements. Pacific Biosciences of California, Inc. ($PACB) has seen a significant +12.7% increase over the last 7 days, trading at $1.42. Illumina ($ILMN) is up +5.74% in the last 7 days, currently at $127.74. Fulgent Genetics, Inc. ($FLGT) shows a +5.05% 7-day change and a strong +15.23% 30-day change, trading at $16.42. These recent upticks suggest some investor interest in the sector, potentially anticipating future growth drivers like the one proposed by HR7118.

Bill Details

Metric	Value
Bill Number	HR7118
Impact Score	4/10Certainty: Introduced/Referred · Financial Magnitude: No explicit funding identified · Strategic Weight: AI qualitative assessment: 6/10 · Market Penetration: 5 companies — broad impact across 2 sectors
Market Sentiment	bullish
Event Date	January 15, 2026
Affected Sectors	Healthcare, Technology
Affected Stocks	$ILMN, Thermo Fisher Scientific ($TMO), $PACB, $BNGO, $FLGT
Source	View on Congress.gov →

Summary

The Genomic Answers for Children’s Health Act of 2026, HR7118, has been introduced and referred to committee, aiming to mandate Medicaid coverage for whole genome and whole exome sequencing for children with specific medical needs. This bill, if enacted, would create a new, guaranteed revenue stream for genomic sequencing and bioinformatics companies by expanding the addressable market within the Medicaid program. While the bill does not specify a direct funding amount, it establishes a new coverage requirement that would increase demand for services provided by companies like Illumina, Thermo Fisher Scientific, Pacific Biosciences, Bionano Genomics, and Fulgent Genetics.

Full AI Market Analysis

The Genomic Answers for Children’s Health Act of 2026 (HR7118) was introduced in the House of Representatives on January 15, 2026, and subsequently referred to the House Committee on Energy and Commerce. This bill seeks to amend title XIX of the Social Security Act to explicitly clarify that whole genome and whole exome sequencing for children with certain medical needs, such as genetic disorders, rare diseases, or conditions of unknown origin, will be covered under the Medicaid program. This legislative action is currently in its early stages, having only been introduced and referred to committee. This bill does not authorize a specific dollar amount but rather mandates coverage for a specific medical service. By clarifying and mandating Medicaid coverage for whole genome and whole exome sequencing, the bill establishes a new, guaranteed revenue stream for companies providing these services. The funding mechanism would be through the existing Medicaid program, where states, with federal matching funds, would be required to cover these diagnostic tests. This represents an expansion of the addressable market for genomic sequencing and bioinformatics within the Medicaid system, directly benefiting companies involved in providing sequencing technology, reagents, and data analysis services. Structural beneficiaries of this bill, if it progresses, include companies specializing in genomic sequencing and related bioinformatics. Companies such as Illumina ($ILMN), a leader in sequencing technology; Thermo Fisher Scientific ($TMO), which offers a broad range of life science solutions including sequencing instruments and consumables; Pacific Biosciences of California, Inc. ($PACB), known for its long-read sequencing platforms; Bionano Genomics, Inc. ($BNGO), focusing on optical genome mapping; and Fulgent Genetics, Inc. ($FLGT), a provider of genetic testing services, are positioned to see increased demand for their products and services. The bill's current status is early stage, having only been referred to committee, indicating a significant legislative path ahead. Looking at recent market data, Illumina ($ILMN) is currently at $127.74, showing a 7-day change of +5.74% and a 30-day change of -0.39%. Thermo Fisher Scientific ($TMO) is at $488.19, with a 7-day change of +1.7% and a 30-day change of -5.91%. Pacific Biosciences of California, Inc. ($PACB) is trading at $1.42, with a 7-day change of +12.7% and a 30-day change of -6.58%. Bionano Genomics, Inc. ($BNGO) is at $1.15, with a 7-day change of +1.77% and a 30-day change of +1.77%. Fulgent Genetics, Inc. ($FLGT) is at $16.42, with a 7-day change of +5.05% and a 30-day change of +15.23%. The recent positive 7-day changes for these companies, particularly PACB, ILMN, and FLGT, suggest some positive momentum in the sector, though the 30-day changes are mixed. The next legislative steps for HR7118 involve committee consideration, including potential hearings and markups. If approved by the Committee on Energy and Commerce, it would then proceed to a vote in the full House of Representatives. If passed by the House, it would then move to the Senate for similar consideration. Given its early stage, the timeline for potential enactment is uncertain and could extend over several months or longer.